Semaglutide Sales In Russia Increased By 224%

Image is created via Giga Chat

The volume of state purchases of semaglutide also increased from 785 million rubles ($10 million) in 2024 to 2.4 billion rubles ($31 million) in 2025.

In parallel with the growth of semaglutide sales in the Russian market, a new class of drugs appeared in 2025: drugs based on tirzepatide, a dual GLP-1 receptor agonist and a glucose-dependent insulinotropic polypeptide (GIP). The original tirzepatide (brands Mounjaro and Zepbound) was developed by the American company Eli Lilly. In the year of their introduction, domestic analogues achieved sales of 8.9 billion rubles – $115.3 million (918,000 packs).

Semaglutide is the active ingredient in drugs that were initially used to treat type 2 diabetes and later gained widespread use for weight loss. In Russia, semaglutide-based drugs have been available since 2019, but after Novo Nordisk left the Russian market, domestic companies such as Geropharm, Promomed, and PSK Pharma took over their production.

The growth of domestic manufacturers and increased production volumes create a competitive environment that helps to lower prices and make drugs more accessible to patients. Currently, nine companies in Russia have registered drugs containing semaglutide, including R-Pharm, Farmstandard-UfaVita, Amedart, KRKA, and Izvarino Pharma.

Until recently, only the standard dosage of semaglutide was available in Russia, but in 2026, Geropharm announced that it intends to release a Russian analogue of high-dose semaglutide, Wegovy, from Novo Nordisk.

For more information about obesity medication and the availability of modern drugs in Russia, please refer to the Marus Media review.

Source: Forbes